Findings
========

Previously nitric oxide (NO) was postulated to have a negative effect on HIV-1 replication through a cGMP-independent route \[[@B1]\]. However, it was not characterized as to how this cGMP-independent effect manifested mechanistically. On the other hand, it is well-accepted that a major intracellular signaling pathway for NO is through a cytosolic-guanylate cyclase linked cGMP-dependent protein kinase, PKG, pathway \[[@B2]\]. cGMP/PKG has been shown to activate abundantly both CREB \[[@B3]\] and NF-κB \[[@B4],[@B5]\]. Interestingly, to our knowledge, no systematic investigation of cGMP/PKG\'s activity on the HIV-1 LTR has been reported to date.

To address how cGMP/PKG might influence HIV-1 LTR-directed expression, we transfected HeLa cells with a LTR-luciferase reporter with or without a Tat-plasmid \[[@B6]-[@B9]\]- and assayed for expression with or without simultaneously co-transfecting a PKG1β-expression vector \[[@B10]\]- (Figure [1](#F1){ref-type="fig"}). We found that PKG1β-alone activated reporter expression by approximately 4 fold (also see Figure [2B](#F2){ref-type="fig"}) while Tat-alone activated expression by \>45 fold (Figure [1A](#F1){ref-type="fig"}). Co-transfection of LTR-luciferase + Tat + PKG1β activated expression cumulatively to \>175 fold (Figure [1A](#F1){ref-type="fig"}). These results are consistent with PKG1β inducing LTR-driven expression whether in the absence or presence of Tat.

![PKG1β activates expression from the HIV-1 LTR. A) Activation of HIV-1 LTR luciferase by PKG1β. HeLa cells were cultured in medium with 0.1% fetal bovine serum and transfected as indicated with HIV-1 LTR luciferase reporter plasmid in the absence and presence of Tat, and with a PKG1-β expression plasmids. PKG1β was found to increase Tat dependent transcriptional activity of the HIV-1 LTR by four fold. B) Co-transfection of PKG1β and HIV-1 infectious molecular clone, pNL4-3, resulted in dose dependent increase in viral protein expression. Expression of FLAG-tagged transfected PKG1β (top panel) and HIV-1 viral proteins are shown by Western blotting.](1742-4690-4-91-1){#F1}

To verify more physiologically the above LTR-reporter assay, we next checked the effect of PKG1β on an HIV-1 infectious molecular clone, pNL 4-3 (Figure [1B](#F1){ref-type="fig"}). Here, increasing amounts of PKG1β-plasmid were transfected into cells with a constant level of pNL 4-3. Viral proteins expressed from the HIV-1 molecular clone were then measured. Using HIV-specific hyper-immune sera in Western blots, we observed that PKG1β increased pNL 4-3 expression in a dose dependent manner (Figure [1B](#F1){ref-type="fig"}, lanes 2 -- 6). To investigate whether the intact function of PKG1β was needed for this activity, we created two loss-of-function PKG1β deletion mutants (Figure [2A](#F2){ref-type="fig"}). Both deletion mutants were unable to activate either a LTR-reporter (Figure [2B](#F2){ref-type="fig"}) or an HIV-1 infectious molecular clone (Figure [2C](#F2){ref-type="fig"}).

![Intact PKG1 β is required for activation of gene expression. A) Schematic representations are shown of full length PKG1β (pCMV-PKG1β FLAG) and two deletion mutants, pCMV-PKG1β 1--417 FLAG and pCMV-PKG1β Δ349FLAG. Transfected cell lysates (right panel) were analyzed by Western blotting using anti-FLAG antibody for expression. B) Full length PKG1β, but not its deletion mutants, activated LTR-luciferase expression. HeLa cells were transfected with the indicated plasmids. C) Full PKG1β, but not its deletion mutants, activated pNL4-3-expression. Plasmids were transfected into HeLa cells as indicated. C- and N-terminus deletions of PKG1β resulted in loss of activity.](1742-4690-4-91-2){#F2}

Optimal PKG activity is dependent on activation by cGMP \[[@B11]\]. While over expression of exogenously transfected PKG offered significantly measureable effects (Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}), we wished to understand next how cell endogenous PKG might act mechanistically in response to cGMP treatment. Elsewhere, it was reported that NF-κB p65, p52, and p50 are substrate proteins activated by PKG-mediated phosphorylation. Because expression of the HIV-1 LTR is regulated by NF-κB \[[@B12],[@B13]\], we asked if cGMP activated NF-κB in our experimental.

To assess if NF-κB was activated by cGMP, we assayed for enhanced nuclear localization of NF-κB protein p65, which is one measure of activation \[[@B14],[@B15]\]. We treated cells with a cGMP agonist, 8-pCPT-cGMP, and compared results to cells treated with a known NF-κB activator, tumor necrosis factor alpha, TNFα. When cytosolic and nuclear p65 proteins were assayed, we observed that 8-pCPT-cGMP behaved quantitatively very similarly to TNFα in inducing increased NF-κB p65-translocation into the nucleus (Figure [3A](#F3){ref-type="fig"}). This result supports that PKG-activation of HIV-1 (Figures [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}) acts through an NF-κB-mediated process. To confirm that PKG1β can directly activate NF-κβ activity, we transfected a NF-κβ luciferase reporter into cells with or without a co-transfected PKG1β expression plasmid (Figure [3B](#F3){ref-type="fig"}). Results from this assay showed that NF-κβ-dependent luciferase activity was indeed elevated by PKG1β.

![Treatment of HeLa cells with cGMP agonist, 8-(4-chlorophenylthio)guanosine 3\'.5\'-cyclic monophosphate (8-pCPT-cGMP), increased NF-κβ p65 in the nucleus. A) HeLa cells were mock treated or treated with TNFa or 8-pCPT-cGMP as indicated. Nuclear and cytoplasmic fractions were collected and assayed for NF-κβ p65 by Western blotting. Both TNFα and 8-pCPT-cGMP were found to increase nuclear NF-κβ p65 while commensurately decreasing cytoplasmic NF-κβ p65. Western blotting for tubulin controlled for subcellular fractionations. Quantifications of relative distributions of NF-κβ p65 are shown at bottom. B) PKG1β increases expression of NF-κB dependent luciferase. HeLa cells were transfected with NF-κB luciferase reporter plasmid in the presence or absence of co-transfected PKG1β expression plasmid. Cells were harvested 24 hours post-transfection, and cell lysates were assayed for luciferase activity as indicated.](1742-4690-4-91-3){#F3}

A more direct verification of cGMP/PKG\'s role in HIV-1 replication can be established using chemical agonists and antagonists of this pathway seeking for effects on viral infection. Because the NO/cGMP signaling pathway has been reported to function potently in cells of macrophage lineage, we performed infection of monocyte derived macrophages (MDMs) using HIV-1 strain AD8 \[[@B16],[@B17]\]. MDMs infected with AD8 were treated individually with three different drugs. We employed two cGMP agonists (8-pCPT-cGMP, and Sp-8-pCPT-cGMP) and one cGMP antagonist (Rp-8-pCPT-cGMPs) and monitored their impact on HIV-1 replication. Informatively, in two separate experiments, both agonist drugs increased virus replication over control-treated infection, while the cGMP-antagonist drug decreased (or did not affect) virus replication (Figure [4](#F4){ref-type="fig"}).

![Effect of cGMP analogues on pAD8 replication in monocyte derived macrophages (MDM\'s). MDM\'s were cultured in RPMI medium containing 10% human serum, infected 5-7 days post culture with HIV-1 AD8 virus, and cells were treated at time of infection with cGMP agonists -8-pCPT-cGMP and Sp-8-pCPT-cGMP or cGMP antagonist (Rp-8-pCPT-cGMPs). Culture supernatants were collected every third day and assayed for virus production by RT assays. cGMP agonists increased virus production from AD8 infected MDM\'s while cGMP antagonists suppressed virus production.](1742-4690-4-91-4){#F4}

Here, we report evidence that both in the absence and presence of Tat the cGMP/PKG pathway can serve to modulate HIV-1 expression/replication. Understanding how HIV-1 LTR expression is affected by ambient cellular pathways \[[@B18]-[@B20]\] may help to address potential approaches for treating latent HIV-1 infection \[[@B21]\]. The current findings may be important because cGMP is a ubiquitous second messenger that affects multiple cellular pathways in most, if not all, cells. Accordingly, cGMP-influenced pathways are likely to interdigitate with some of the signaling routes utilized by HIV-1 in infected cells \[[@B22]\]. Additionally, because many cGMP chemical agonists and antagonists are available \[[@B23],[@B24]\], practical chemotherapeutic interventions in these pathways (if they should be useful for anti-viral purposes) could be amenable.

Competing interests
===================

The author(s) declare that they have no competing interests.

Authors\' contributions
=======================

JHL and VY carried out the experiments. JHL, VY, and KTJ conceived of the study and wrote the manuscript.

Acknowledgements
================

Work in Kuan-Teh Jeang\'s laboratory is supported in part by intramural funding from NIAID, NIH; and by the intramural AIDS targeted antiviral program (IATAP) from the Office of the Director, NIH. We thank Dr. S.M. Lohmann for PKG1β expression plasmid.
